Examining the divestment risks, as more large companies look to spin off consumer health and other business units to focus on branded pharmaceuticals
William Borden
Advertisement
Articles by William Borden
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: Novartis Buys Avidity for $12B, and Trump Threatens 10% Tariff Hike on Canada
2
Trump Threatens 10% Tariff Hike on Canadian Imports After Controversial Reagan Ad Airs During World Series
3
LogiPharma USA 2025: Pharma Supply Chains Evolve Toward Real-Time Visibility and End-to-End Control
4
Why DTC Drug Models Must Evolve From Access to True Patient Support
5
